Literature DB >> 11422479

Lung carcinoma with rhabdoid cells: a clinicopathological study and survival analysis of 14 cases.

H Shimazaki1, S Aida, M Sato, H Deguchi, Y Ozeki, S Tamai.   

Abstract

AIMS: We determined the clinicopathological features of primary lung carcinomas with rhabdoid cells by defining the immunophenotype of rhabdoid cells and analysing survival. METHODS AND
RESULTS: Rhabdoid cells are distinctive in having an eccentric nucleus and a large intracytoplasmic inclusion on routinely stained sections. Based on the number of rhabdoid cells, 45 cases of large cell carcinoma were divided into the following three types: lung tumour with a rhabdoid phenotype (LTRP) (n=4), lung carcinoma with a small number of rhabdoid cells (LCSR) (n=10), large cell carcinoma containing no rhabdoid cells (LCNR) (n=31). LTRP is composed of at least 10% rhabdoid cells. In LCSR the percentage of rhabdoid cells is less than 10%. LTRP and LCSR are associated with locally advanced disease. Immunohistochemical stains were positive for epithelial markers in all LTRP and eight LCSR, for neuroendocrine markers in one LTRP and three LCSR. The outcome is worse for patients with LTRP than LCSR or LCNR. LCSR shows a trend close to LCNR. Stage-matched survival analysis, however, revealed no statistically significant difference among the histological subtypes.
CONCLUSIONS: Rhabdoid cells are heterogeneous except for epithelial markers and vimentin positivity. Less than 5% of rhabdoid cells has a negligible effect on prognosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11422479     DOI: 10.1046/j.1365-2559.2001.01145.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  8 in total

Review 1.  [Lung cancer. Developments, concepts and preview of the new WHO classification].

Authors:  I Petersen; A Warth
Journal:  Pathologe       Date:  2014-11       Impact factor: 1.011

2.  Mutation of the INI1 gene in composite rhabdoid tumor of the endometrium.

Authors:  Ludvik R Donner; Luanne M Wainwright; Fan Zhang; Jaclyn A Biegel
Journal:  Hum Pathol       Date:  2007-03-21       Impact factor: 3.466

3.  Atypical teratoid/rhabdoid tumor arising in the setting of a pleomorphic xanthoastrocytoma.

Authors:  Geeta Chacko; Ari G Chacko; Christopher P Dunham; Alexander R Judkins; Jaclyn A Biegel; Arie Perry
Journal:  J Neurooncol       Date:  2007-04-13       Impact factor: 4.130

Review 4.  Lung cancer: developments, concepts, and specific aspects of the new WHO classification.

Authors:  Iver Petersen; Arne Warth
Journal:  J Cancer Res Clin Oncol       Date:  2015-07-22       Impact factor: 4.553

5.  Expression of adhesion molecules and cytokeratin 20 in merkel cell carcinomas.

Authors:  Yasushi Tanaka; Toshiaki Sano; Zhi Rong Qian; Mitsuyoshi Hirokawa
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

6.  A case of lung carcinoma with rhabdoid phenotype mimicking an aspergilloma in patient with recurrent hemoptysis.

Authors:  Moo Woong Kim; Soo Jung Rew; Seo Joon Eun; Ui Sin Lee; Chan Woo Park; Jong Pil Jeong; Young Choon Ko
Journal:  Tuberc Respir Dis (Seoul)       Date:  2014-07-31

Review 7.  Neuroendocrine tumor of the pancreas with rhabdoid feature.

Authors:  Tetsuyuki Miyazaki; Shinichi Aishima; Minoru Fujino; Keigo Ozono; Yuichiro Kubo; Yasuhiro Ushijima; Takashi Osoegawa; Eikichi Ihara; Itou Tetsuhide; Takao Ohtsuka; Masafumi Nakamura; Yoshinao Oda
Journal:  Virchows Arch       Date:  2018-06-24       Impact factor: 4.064

8.  SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas.

Authors:  Natasha Rekhtman; Joseph Montecalvo; Jason C Chang; Deepu Alex; Ryan N Ptashkin; Ni Ai; Jennifer L Sauter; Brie Kezlarian; Achim Jungbluth; Patrice Desmeules; Amanda Beras; Justin A Bishop; Andrew J Plodkowski; Mrinal M Gounder; Adam J Schoenfeld; Azadeh Namakydoust; Bob T Li; Charles M Rudin; Gregory J Riely; David R Jones; Marc Ladanyi; William D Travis
Journal:  J Thorac Oncol       Date:  2019-11-18       Impact factor: 15.609

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.